Influenza A virus H7N9 surface antigen (H7N9 HA/NA)

Influenza A virus H7N9 surface antigens, primarily comprising the glycoproteins hemagglutinin (HA) and neuraminidase (NA), are the principal targets for the host immune system and antiviral therapeutics. Hemagglutinin functions as a lectin that mediates viral attachment to host sialic acid receptors and facilitates membrane fusion for entry into respiratory epithelial cells. Neuraminidase is an enzyme that cleaves sialic acid residues to enable the release of progeny virions and prevent viral aggregation. These antigens are critical determinants of the virus's pathogenicity and zoonotic potential; for instance, specific mutations in H7 HA enhance its affinity for human-type alpha-2,6-linked sialic acid receptors. In clinical practice, these antigens are the focus of vaccine development and are targeted by neuraminidase inhibitors such as oseltamivir and zanamivir. However, the high mutation rate of the H7N9 virus leads to antigenic drift and the emergence of drug-resistant variants, such as those possessing the R294K mutation in NA, which complicates pandemic preparedness and therapeutic efficacy.

Other names

H7N9 surface proteinsH7 hemagglutininN9 neuraminidaseInfluenza A(H7N9) antigensAvian influenza H7N9 antigensH7N9 viral glycoproteins

Inhibition of viral neuraminidase to prevent progeny release; neutralization of hemagglutinin to block viral entry; inhibition of viral RNA polymerase to halt replication.